Application of Zhongwinning in preparation of anti-aging drugs

Abstract

The invention belongs to the technical field of new application of medicines, and provides application of Zhongwinning in preparation of anti-aging medicines. Experimental research proves that Zhongutanin can play an anti-aging role in multiple ways, and can significantly increase spleen and thymus coefficients of a D-galactose aging model mouse; the MDA content activity of a D-galactose senescence-induced model mouse is obviously reduced, and the activity of SOD and GSH-Px of the D-galactose senescence-induced model mouse is improved; the body inflammation level is obviously reduced; the content of LPO and LF and the activity of MAO-B in the brain tissue of a D-galactose senescence-induced model mouse are obviously reduced; the loss of hydroxyproline and hyaluronic acid in the aged skin of a D-galactose aging-induced model mouse can be slowed down; a Morris water maze experiment test result shows that the Zhongwinning has the effect of improving the learning and memory ability of an aging model mouse. Therefore, the Zhongwinning has a certain application prospect in preparation of anti-aging drugs.

Description

Technical Field

[0001] The invention belongs to the technical field of new drug applications, and in particular relates to the application of Zhongwuning in the preparation of anti-aging drugs. Background Art

[0002] Biologically, aging is a spontaneous and inevitable process of organisms over time. It is a complex natural phenomenon, manifested as structural degeneration and functional decline, and reduced adaptability and resistance. In physiology, aging is considered as the individual development history from the fertilized egg to old age. Pathologically, aging is the result of stress and strain, injury and infection, immune response decline, malnutrition, metabolic disorders, and the accumulation of neglect and drug abuse. In addition, from a sociological perspective, aging is a person's loss of interest in new things, detachment from reality, and a preference for nostalgia.

[0003] Among the many factors of aging, oxidative stress damage caused by free radicals and insufficient blood supply to the brain are two very important factors.

[0004] Oxidative stress injury refers to the abnormality of macromolecular oxygen metabolism in the body, which leads to the appearance of a large number of free radicals in the body. These free radicals can damage cells, proteins and DNA, leading to aging, and may also cause diseases such as diabetes, arteriosclerosis and Alzheimer's disease, which are very harmful to the body. In addition, arteriosclerosis and sequelae of cerebral thrombosis can increase the resistance of cerebral circulation, slow down the cerebral blood flow, and reduce the blood and oxygen supply to the brain, which in turn causes the accumulation of oxygen free radicals and excitatory amino acids in brain cells. The delayed damage and brain cell degeneration caused by this will affect people's learning, memory and behavioral functions.

[0005] In recent years, drug anti-aging has become a hot topic in the field of aging. Metformin, rapamycin, etc. have been proven to significantly delay the aging process and prevent aging-related diseases. The importance of drug anti-aging to human health is becoming increasingly prominent. However, chemical drugs have many adverse reactions, specific targets, and multiple drug resistance, which makes their scientific nature of anti-oxidative anti-aging controversial. Natural medicines have a long history and are an important source of drug lead compounds and synthetic drugs. They have few toxic and side effects and a wide range of long-lasting effects. With the development of science and technology, more and more experimental studies on natural medicines are being conducted, and their pharmacology and efficacy are gradually becoming clear.

[0006] Mesaconine (CAS NO.: 6792-09-2; molecular formula: C 24 H 39NO9) is a new type of alkaloid with medicinal value. It has a clear chemical structure and can be obtained by raw material extraction or chemical synthesis. Zhongwu Ning has a significant effect on improving cardiac function and can effectively prevent and treat or improve acute heart failure caused by myocardial ischemia-reperfusion injury. However, there is no report on the treatment or improvement of Zhongwu Ning for anti-aging. Summary of the invention

[0007] In view of the above-mentioned deficiencies in the prior art, the object of the present invention is to provide the application of Zhongwu Ning in the preparation of anti-aging drugs. Studies have confirmed that Zhongwu Ning can play an anti-aging role in a variety of ways. It can significantly increase the spleen and thymus coefficients of D-galactose-induced aging model mice, significantly reduce the malondialdehyde (MDA) content activity of mice, improve the activity of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) of mice, reduce the level of inflammation in the body, reduce the content and activity of lipid peroxides (LPO), lipofuscin (LF) and type B monoamine oxidase (MAO-B) in mouse brain tissue; and can slow down the loss of hydroxyproline and hyaluronic acid in the aging skin of D-galactose-induced aging model mice; Morris water maze test results show that Zhongwu Ning has the effect of improving the learning and memory ability of aging model mice. Therefore, Zhongwu Ning has a certain application prospect for the preparation of anti-aging drugs.

[0008] In order to achieve the above object, the solution adopted by the present invention is:

[0009] Application of Zhongwuning or its pharmaceutically acceptable salt in preparing anti-aging drugs.

[0010] Furthermore, in a preferred embodiment of the present invention, the anti-aging drug is a preparation prepared with Zhongwuning or a pharmaceutically acceptable salt thereof as an active ingredient and adjuvants or auxiliary ingredients commonly used in pharmacy.

[0011] Furthermore, in a preferred embodiment of the present invention, the pharmaceutically acceptable salt is an inorganic salt or an organic salt.

[0012] Furthermore, in a preferred embodiment of the present invention, the dosage form of the preparation includes a liquid preparation, a solid preparation or a semisolid preparation.

[0013] The beneficial effects of the application of Zhongwuning provided by the present invention in the preparation of anti-aging drugs are:

[0014] This application first discovered the use of Zhongwu Ning in the preparation of anti-aging drugs. Studies have confirmed that:

[0015] (1) Zhongwuning can significantly increase the spleen and thymus indexes of D-galactose-induced aging model animals;

[0016] (2) Zhongwuning can significantly reduce the MDA content and activity of brain tissue in D-galactose-induced aging model animals and increase the activity of SOD and GSH-Px;

[0017] (3) Zhonguning can significantly reduce the levels of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in the serum of D-galactose-induced aging model animals, and has a strong inhibitory effect on the secretion of inflammatory cytokines;

[0018] (4) Zhongwuning can significantly reduce the content of LPO and LF and the activity of MAO-B in the tissues of D-galactose-induced aging model animals;

[0019] (5) Zhongwu Ning can slow down the loss of hydroxyproline and hyaluronic acid in the aged skin of D-galactose-induced aging model mice;

[0020] (6) The results of Morris water maze test showed that Zhongwu Ning can improve the learning and memory abilities of aging model mice.

[0021] The above test results indicate that Zhongwu Ning has application prospects in the preparation of anti-aging drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 is a comparison chart of IL-1β content in serum samples of each group of mice provided in Experimental Example 1 of the present invention;

[0023] Figure 2 is a comparison chart of TNF-α content in serum samples of various groups of mice provided in Experimental Example 1 of the present invention;

[0024] Figure 3 is a comparison chart of the hydroxyproline content in the skin of mice in each group provided in Experimental Example 1 of the present invention;

[0025] Figure 4 It is a comparison chart of the hyaluronic acid content in the skin of each group of mice provided in Experimental Example 1 of the present invention. DETAILED DESCRIPTION

[0026] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0027] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0028] Example 1

[0029] 1. Experimental animals: ICR mice, half male and half female, weight 18-22 g, provided by Chengdu Dashuo Biotechnology Co., Ltd., production license number: SCXK (Sichuan) 2015-030.

[0030] 2. Experimental methods

[0031] 2.1 Animal modeling and group administration

[0032] 40 ICR mice were taken, half male and half female, of which 10 were taken as the normal control group, and 30 mice were randomly divided into three groups: (1) model group: distilled water; (2) positive group: Yanshou tablets (provided by Dali Bai Autonomous Prefecture Traditional Chinese Medicine Pharmaceutical Co., Ltd.), 0.702g / kg; (3) Zhongwuning group (Zhongwuning was provided by Good Doctor Pharmaceutical Group Co., Ltd.): Zhongwuning, 6.7mg / kg. All mice were fed with ordinary feed. Except for the normal control group, the rest of the animals were subcutaneously injected with 5% D-galactose in the back every day, 0.5mL / mouse, for 6 consecutive weeks to create an aging model. Each drug was prepared into the required concentration, and at the same time as the modeling, each group of animals were gavaged and administered once a day for 6 consecutive weeks.

[0033] 2.2 Measurement indicators and methods

[0034] 2.2.1 Organ index: 1 hour after the last administration, blood was collected from the eyeball of the animal, and serum was obtained by centrifugation at 5000 x g for 15 min at 4°C. The animal was euthanized, and the spleen and thymus were weighed to calculate the organ index.

[0035] 2.2.2 Determine the content and activity of MDA, SOD, and GSH-Px according to the instructions of the biochemical kit (kit, Nanjing Jiancheng Bioengineering Institute, batch number: 20160607).

[0036] 2.2.3 Determine IL-1β and TNF-α in mouse serum samples according to the instructions of the ELISA kit (Suzhou Calvin Biotechnology Co., Ltd., batch number: E20170201A).

[0037] 2.2.4 The left cerebral tissue of the animal was taken and made into homogenate, and the LPO, LF, MAO-B content and activity (ELISA detection kit, Suzhou Calvin Biotechnology Co., Ltd., batch number: E20170201A) were determined according to the instructions of the ELISA kit.

[0038] 2.2.5 After depilating the dorsal part of the mouse, take skin tissue about 1 cm 2 (Avoid bringing in white adipose tissue) and quick-freeze in liquid nitrogen; take a small piece of mouse skin tissue, remove fat with acetone-ether (1:1), chop, dry, and then accurately weigh 20 mg, and determine the levels of hydroxyproline and hyaluronic acid in the sample according to the operating instructions of the mouse hyaluronic acid and hydroxyproline kit.

[0039] 2.3 Statistical methods: The experimental data were analyzed using SPSS18.0 statistical software. The data results were expressed as mean ± standard deviation (x ± s). One-way analysis of variance was used for comparison of means among multiple groups, and the SNK method was used for pairwise comparison of means among multiple groups. P < 0.05 was considered statistically significant.

[0040] 3. Experimental results

[0041] (1) Table 1 shows the organ indexes of mice in each group:

[0042] Table 1 Organ indexes of mice in each group

[0043] Group No. Spleen (g / 100g BW) Thymus (g / 100g BW) Normal control group 0.452±0.062 0.139±0.022 Model Group <![CDATA[0.275±0.035 # ]]> <![CDATA[0.084±0.018 ## ]]> Positive group <![CDATA[0.393±0.071 * ]]> <![CDATA[0.133±0.031 ** ]]> Zhongwuning Group <![CDATA[0.382±0.052 * ]]> <![CDATA[0.125±0.022 ** ]]>

[0044] Note: Compared with the normal control group, # P<0.05, ## P<0.01; compared with the model group, * P<0.05, ** P<0.01.

[0045] The thymus is the central organ of immune regulation and plays an important role in the body's cellular immune function and the occurrence of immune responses; the spleen is the largest peripheral immune organ, which provides a place for various mature lymphocytes to settle and produce immune responses. The aging of the body will cause the weight of the thymus and spleen to become lighter, and the thymus and spleen coefficients can indirectly reflect the degree of aging of the body.

[0046] The data in Table 1 show that compared with the normal control group, the spleen and thymus coefficients of the model group animals were significantly reduced (P < 0.01); compared with the model group, the positive group using Yanshou tablets can significantly increase the spleen coefficient (P < 0.05) and thymus coefficient (P < 0.01), and the effect of the Zhongwuning group on improving the spleen coefficient and thymus coefficient is close to that of the positive group, and is significantly improved compared with the model group.

[0047] (2) Table 2 shows the MDA content, SOD and GSH-Px activities in the serum of mice in each group.

[0048] Group No. MDA (nmol / mL) SOD(U / mL) GSH-Px(mg / L) Normal control group 3.50±0.79 210.25±31.45 120.67±18.18 Model Group <![CDATA[9.21±0.88 ## ]]> <![CDATA[116.24±30.07 ## ]]> <![CDATA[61.76±11.81 ## ]]> Positive group <![CDATA[6.25±0.67 * ]]> <![CDATA[140.83±27.66 * ]]> <![CDATA[85.71±11.12 * ]]> Zhongwuning Group <![CDATA[7.04±0.55 * ]]> <![CDATA[135.66±28.16 * ]]> <![CDATA[82.33±13.62 * ]]>

[0049] Note: Compared with the normal control group, ## P<0.01; compared with the model group, * P<0.05.

[0050] MDA is a product of intracellular lipid peroxidation and an important indicator of oxidative stress. In cells, lipid peroxidation produces MDA, which is a highly reactive metabolite that can covalently bind to proteins, nucleic acids and other biomolecules in cells, leading to cell function damage and inflammatory response. Therefore, by measuring the content of MDA, it is possible to determine whether the degree of oxidative stress in individual cells has increased, thereby predicting the risk of related diseases, and to evaluate the antioxidant capacity and therapeutic effect of drugs. The content of MDA in the brain tissue of rats with cerebral ischemia increased sharply.

[0051] SOD belongs to the antioxidant enzyme system and is praised by the World Health Organization as the most promising medicinal enzyme for development and application in the 21st century. It is the number one killer of oxygen free radicals in the body and the scavenger in the human body. It can convert superoxide anions into harmless oxygen and hydrogen peroxide, thereby removing harmful free radicals, improving dyslipidemia, preventing atherosclerosis, preventing the occurrence of cardiovascular diseases, and eliminating lipid peroxidation in tissue cells, thereby delaying aging.

[0052] GSH-Px is an important peroxide decomposing enzyme widely present in the body. Its physiological function is mainly to catalyze GSH to participate in peroxidation reaction, remove peroxides and hydroxyl free radicals produced in the process of cell respiration and metabolism, thereby reducing the peroxidation of polyunsaturated fatty acids in cell membranes. The body can effectively remove active oxygen such as lipid peroxides and terminate free radical chain reactions through the GSH-Px enzymatic reaction, thereby defending against damage caused by lipid peroxidation.

[0053] The D-galactose-induced aging model is very similar to the human natural aging model. The data in Table 2 show that the MDA content and activity of the brain tissue of animals treated with D-galactose in the model group increased (P < 0.01), while the activities of SOD and GSH-Px decreased (P < 0.01).

[0054] The data in Table 2 show that compared with the model group, the positive group using Yanshou Tablets can significantly reduce the activity of MDA content (P < 0.05), and increase the activity of SOD and GSH-Px (P < 0.05). The effect of the Zhongwu Ning group on reducing the activity of MDA content and increasing the activity of SOD and GSH-Px is close to that of the positive group, and compared with the model group, it has a significant improvement (P < 0.05).

[0055] (3) Chronic inflammation is one of the main causes of accelerated aging. Aging bodies are accompanied by high levels of inflammatory cytokines. When the body is in an inflammatory state, the activity of matrix metalloproteinases increases, resulting in increased degradation of the extracellular matrix. IL-1β is the abbreviation of interleukin 1β, a cytokine that plays an important role in immune response and inflammatory response. IL-1β is a typical proinflammatory cytokine that can induce the release of inflammatory cytokines such as IL-6 and TNF-α and stimulate T cell activation, which can stimulate local and systemic inflammatory responses. TNF-α generally refers to tumor necrosis factor-α. If tumor necrosis factor-α increases, it usually indicates that the patient may have an inflammatory response or tumor lesions in the body. Tumor necrosis factor-α is a phenotype of tumor necrosis factor, which is mainly derived from monocytes and phagocytes. It can cause bleeding and necrosis of tumor tissues, and has a killing effect. It can also cause anti-infection inflammatory response effects and play an important role in the regulation of immune cells.

[0056] Figure 1 and Figure 2 The results showed that compared with the normal control group mice, the levels of inflammatory cytokines IL-1β and TNF-α in the model group mice were significantly increased (P<0.01), indicating that there was a high level of inflammation in the model group mice (compared with the normal control group, the model group P<0.01).

[0057] After oral administration of Zhongwuning group and positive group, the concentration of IL-1β and TNF-α in mouse serum was significantly reduced (compared with model group, P<0.01), which further indicated that Zhongwuning group had a strong inhibitory effect on the secretion of inflammatory cytokines. Zhongwuning has the effect of reducing the level of inflammation in the body.

[0058] (4) Table 3 shows the content of LPO and LF and the activity of MAO-B in the brain tissue of mice in each group:

[0059] Table 3 LPO, LF content and MAO-B activity in brain tissue of mice in each group

[0060] Group No. LPO (nmol / mL) LF (ng / mL) MAO-B (U / mL) Normal control group 24.66±1.15 18.82±2.22 28.21±1.08 Model Group <![CDATA[32.15±1.33 # ]]> <![CDATA[23.96±2.03 # ]]> <![CDATA[39.27±1.56 # ]]> Positive group <![CDATA[26.23±1.53 * ]]> <![CDATA[19.45±2.88 * ]]> <![CDATA[29.49±1.82 * ]]> Zhongwuning Group <![CDATA[27.05±1.42 * ]]> <![CDATA[20.02±2.33 * ]]> <![CDATA[30.52±1.66 * ]]>

[0061] Note: Compared with the normal control group, # P<0.05; compared with the model group, * P<0.05.

[0062] LF, also known as senile hormone, accumulates more with age and is one of the important signs of aging. It is a yellow-brown irregular body deposited in aging cells of nerve, myocardium, liver and other tissues. Its contents are substances with different electron densities, lipid droplets, vesicles, etc. It is a residual body formed by substances that can no longer be digested after the action of lysosomes.

[0063] MAO-B is also known as the aging enzyme. The activity of monoamine oxidase in the brain increases with age, so its activity is closely related to aging. It is widely present in the liver, kidneys, brain and other areas of the body and is the main enzyme that induces the metabolism of monoamine substances in the body.

[0064] LPO is the product of the reaction between oxygen free radicals and polyunsaturated fatty acids. Under normal circumstances, the content of LPO is extremely low. When the body is damaged by free radicals and pathological changes occur, or when aging occurs with age, the enhanced lipid peroxidation reaction can lead to an increase in LPO. Therefore, LPO can be used as one of the signs of aging.

[0065] The data in Table 3 show that compared with the normal control group, the LPO and LF contents and MAO-B activity in the brain tissue of the animals in the model group were significantly increased (P < 0.05); compared with the model group, the positive group using Yanshou tablets can significantly reduce the LPO and LF contents and MAO-B activity in the brain tissue of the animals (P < 0.05), and the effect of the Zhongwuning group on reducing the LPO and LF contents and MAO-B activity is close to that of the positive group, and compared with the model group, it has a significant decrease (P < 0.05).

[0066] (5) During the aging process, the body's antioxidant system capacity decreases. Human aging is accompanied by a decrease in the content of skin collagen and hyaluronic acid.

[0067] Figure 3 and Figure 4 The results showed that D-galactose treatment significantly reduced the content of hydroxyproline and hyaluronic acid in the skin of the model mice (P<0.01), accelerating skin aging. After oral administration of Zhongwuning group and positive group, the loss of hydroxyproline and hyaluronic acid in the aging skin of D-galactose-induced aging model mice was slowed down.

[0068] Example 2

[0069] 1. Experimental animals: Same as in Example 1.

[0070] 2. Experimental methods:

[0071] 2.1 Animal modeling and group administration

[0072] Same as Example 1.

[0073] 2.2 Measurement indicators and methods

[0074] After the administration, all mice were subjected to continuous Morris water maze test starting from the second day, followed by positioning navigation test and space exploration test.

[0075] Before each experiment, all mice were moved into the behavioral experiment room 1 hour in advance to acclimate to the environment of the room. The Morris water maze experiment used the Morris water maze experimental apparatus, which included a movable platform and a pool. The bottom and surrounding walls of the pool were dyed white, and a certain amount of titanium dioxide was poured into the clean water in the pool in advance to conceal the platform. A camera connected to a computer was installed directly above the pool to record the complete swimming trajectory of the mice within a certain period of time, and automatically calculate the total swimming distance, time, swimming speed and time required to find the platform of the mice.

[0076] Positioning navigation experiment: Training was conducted twice a day, once in the morning and once in the afternoon. The mice were placed in the water from a fixed entry point facing the pool wall. The timer was started at the same time as they were placed in the water. The time required for the mice to find the platform hidden underwater was recorded. The result was the escape latency. If the mouse failed to successfully find the platform within 60 seconds, the experimenter would guide the mouse to the platform hidden underwater and let it stand on the platform for 15 seconds to observe the surrounding environment. The latency was recorded as 60 seconds.

[0077] Spatial exploration experiment: The positioning navigation experiment lasted for 5 days. On the 6th day, the hidden platform in the water was removed, and any position in the pool was fixed as the entry point for the experiment. The mice were allowed to swim in the pool to explore and find the platform for 60 seconds. The escape latency, total swimming time in the quadrant where the original platform was located, and the number of times they crossed the original platform during the experiment were recorded.

[0078] 2.3 Statistical methods: The experimental data were analyzed using SPSS25.0 statistical software. The means among multiple groups were compared using one-way analysis of variance, and the t-test was used for comparison between two groups. P < 0.05 was considered statistically significant.

[0079] 3. Experimental results

[0080] (1) The results of the positioning navigation experiment are shown in Table 4:

[0081] Table 4 Latency of mice in each group in the positioning navigation experiment

[0082] Group No. Day 1 the next day Day 3 Day 4 Day 5 Normal control group 55.2±1.6 49.3±1.3 35.6±1.8 28.4±1.0 20.6±2.0 Model Group 63.0±1.0 57.2±1.6 54.6±1.2 <![CDATA[55.1±1.6 ## ]]> <![CDATA[52.3±2.1 ## ]]> Positive group 62.1±1.2 54.4±1.3 48.3±1.5 39.1±1.2 <![CDATA[35.5±1.6 ** ]]> Zhongwuning Group 61.2±1.1 52.1±1.4 45.3±1.0 30.2±1.3 <![CDATA[21.5±1.6 ** ]]>

[0083] Note: Compared with the normal control group, ## P<0.01; compared with the model group, ** P<0.01.

[0084] The results in Table 4 show that with the extension of training time, except for the model group, the time for mice in other groups to find the platform gradually shortened. Compared with the normal control group, the latency of mice in the model group to find the platform on the 4th and 5th days of training was significantly prolonged (P < 0.01).

[0085] Compared with the model group, on the third day of training, the latency of the mice in the Zhongwuning group and the positive group to find the platform was significantly shortened. On the fifth day of training, the latency of the mice in the Zhongwuning group and the positive group to find the platform was significantly shortened compared with the model group, with statistical differences (P < 0.01).

[0086] (2) The results of the space exploration experiment are shown in Table 5:

[0087] Table 5 Latency and crossing times of mice in each group in the space exploration experiment

[0088]

[0089]

[0090] Note: Compared with the normal control group, # P<0.05, ## P<0.01; compared with the model group, * P<0.05, ** P<0.01.

[0091] The results in Table 5 showed that compared with the normal control group, the mice in the model group stayed in the quadrant where the platform was located for a significantly longer time (P < 0.01), crossed the original platform less frequently (P < 0.05), and swam a shorter distance.

[0092] Compared with the mice in the model group, the latency period of the mice in the Zhongwuning group and the positive group was significantly shortened, the time they stayed in the quadrant where the platform was located was significantly shortened (P < 0.01), the swimming distance was prolonged, and the number of times they crossed the escape platform increased (P < 0.05).

[0093] In summary, the study confirmed that Zhongwu Ning can play an anti-aging role in many ways. It can significantly increase the spleen and thymus coefficients of D-galactose-induced aging model mice; significantly reduce the MDA content and vitality of D-galactose-induced aging model mice, and increase the activity of SOD and GSH-Px of D-galactose-induced aging model mice; significantly reduce the level of inflammation in the body; significantly reduce the LPO and LF content and MAO-B activity in the brain tissue of D-galactose-induced aging model mice; Morris water maze test results show that the latency of the model group mice was prolonged, the number of crossing the platform and the number of effective areas were reduced, and the learning and memory ability of the mice decreased. The learning and memory ability of the mice in the Zhongwu Ning group was shorter than that of the model group mice, and the number of crossing the platform and the number of effective areas was increased. It was confirmed by experimental methods that Zhongwu Ning has the ability to improve the learning and memory ability of aging model mice. Therefore, Zhongwu Ning has a certain application prospect for the preparation of anti-aging drugs.

[0094] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Use of Zhongwuning or its pharmaceutically acceptable salt in the preparation of anti-aging drugs.

2. The use according to claim 1, characterized in that: The anti-aging drug is a preparation prepared by taking Zhongwuning or its pharmaceutically acceptable salt as the active ingredient and adding auxiliary materials or auxiliary ingredients commonly used in medicine.

3. The use according to claim 2, characterized in that: The pharmaceutically acceptable salt is an inorganic salt or an organic salt.

4. The use according to claim 2, characterized in that: The dosage form of the preparation includes a liquid preparation, a solid preparation or a semisolid preparation.

Images